Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: A large single-center experience of 40 patients

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 1296-1303

  Saxena, Akshat ^a,b   Kapoor, Jada ^b   Meteling, Baerbel ^a   Morris, David L ^b   Bester, Lourens ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PATIENT SAFETY; RADIOEMBOLIZATION; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; BRACHYTHERAPY; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; YTTRIUM RADIOISOTOPES;

EID: 84896092889     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3436-1     Document Type: Article

References (28)

1. Australian Institute of Health and Welfare. Cancer in Australia: an overview, 2012. Canberra: Australian Institute of Health and Welfare; 2012.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
3. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179-83.
4. Schneebaum S, Walker MJ, Young D, Farrar WB, Minton JP. The regional treatment of liver metastases from breast cancer. J Surg Oncol. 1994;55:26-31; discussion 2.
5. Martin RC, Robbins K, Fages JF, et al. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat. 2012;132:753-63.
6. Chua TC, Saxena A, Liauw W, Chu F, Morris DL. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer. 2011;47:2282-90.
7. Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524-35.
8. Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17:1546-54.
9. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251:910-6.
10. Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol. 2011;137:865-73.
11. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227-34.
12. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69:800-4. (Pubitemid 47418394)
13. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683-90.
14. Bangash AK, Atassi B, Kaklamani V, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621-8. (Pubitemid 46661173)
15. Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol. 2013;23:182-9.
16. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-78. (Pubitemid 44259009)
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
18. Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol. 2008;19:1427-33.
19. Haug AR, Tiega Donfack BP, Trumm C, et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012;53:371-7.
20. Smits ML, Prince JF, Rosenbaum CE, et al. Intra-arterial radioembolization of breast cancer liver metastases: a structured review. Eur J Pharmacol. 2013;709:37-42.
21. Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhonen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol. 1994;12:1639-47. (Pubitemid 24245000)
22. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006;98:1285-91. (Pubitemid 44530724)
23. Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat. 1997;44:211-5. (Pubitemid 27296380)
24. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
25. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771-85.
26. Campora E, Gardin G, Gasco M, Rosso R, Santi L. Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit? Anticancer Res. 1999;19:3429-32. (Pubitemid 30000198)
27. Camacho LH, Kurzrock R, Cheung A, et al. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer. 2007;109:2190-6. (Pubitemid 46801547)
28. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology. 2003;229:457-64. (Pubitemid 37310833)